PDCD1 and hepatocellular carcinoma: A recent study reported outcomes of 25 patients with advanced HCC treated with ipilimumab and PD-1 inhibition with pembrolizumab or nivolumab after prior anti-PD-1/PD-L1 monotherapy (Wong et al. 2021).